Orphanet Journal of Rare Diseases (Dec 2021)

National Rare Diseases Registry System (NRDRS): China’s first nation-wide rare diseases demographic analyses

  • Jian Guo,
  • Peng Liu,
  • Limeng Chen,
  • Haohan Lv,
  • Jie Li,
  • Weichao Yu,
  • Kaifeng Xu,
  • Yicheng Zhu,
  • Zhihong Wu,
  • Zhuang Tian,
  • Ye Jin,
  • Rachel Yang,
  • Weihong Gu,
  • Shuyang Zhang,
  • the Administrative Group of National Rare Diseases Registry System of China

DOI
https://doi.org/10.1186/s13023-021-02130-7
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background China has made tremendous progresses in serving the needs of its people living with rare diseases in the past decade, especially over the last 5 years. The Chinese government’s systematic approach included a series of coordinated initiatives, amongst these are: forming the Rare Disease Expert Committee (2016), funding the “Rare Diseases Cohort Study” (2016–2020), and publishing its first “Rare Disease Catalog” (2018). Herein, we present the National Rare Diseases Registry System (NRDRS)—China’s first national rare diseases registry, and the analysis of cases registered in the first 5 years ending Dec 31, 2020. Results The total 62,590 cases covered 166 disease/disease types, forming 183 disease cohorts. The data from nearly 22% of them (13,947 cases) is also linked to valuable biological samples. The average age of definitive diagnosis was 30.88 years; 36.07% of cases were under 18 years of age. Regional distribution analysis showed 60% of cases were from the more developed, wealthier East and North China, suggesting the local availability of quality care and patients’ financial status were key access factors. Finally, 82.04% of cases were registered from the five clinical departments: Neurology, Endocrine, Hematology, Cardiovascular, and Nephrology, suggesting that either these are most affected by rare diseases, or that there were disease non-specific ascertainment factors. Conclusions The preliminary analysis of the first 5-year’s data provides unique and valuable insight on rare disease distribution in China, and higlights the directions for enhancing equity, scale and utility.

Keywords